Cannabigerol, a non-intoxicating compound from the cannabis plant, has gained popularity as a dietary supplement for its purported anti-inflammatory and brain-protecting properties. However, new laboratory research published in Toxicology suggests that its effects on brain immune cells are inconsistent and heavily dependent on concentration. Low doses left cells intact, yet all but the smallest broke isolated DNA in a cell-free test. The highest concentration killed cells and triggered severe chemical stress, and lower doses failed to reliably calm an induced inflammatory response.
Cannabigerol is a naturally occurring chemical belonging to a class of molecules called phytocannabinoids, which are produced by the Cannabis sativa plant. Unlike tetrahydrocannabinol, the primary compound responsible for the cannabis “high,” cannabigerol does not cause intoxication or impair coordination, making it an attractive candidate for everyday supplements and potential therapies. Early human research has added to that interest, including a placebo-controlled trial in adults that found taking 20 milligrams of hemp-derived cannabigerol reduced feelings of anxiety and stress and modestly improved verbal memory recall compared to a placebo.
Beyond mood and memory, scientists have investigated whether cannabigerol can protect the nervous system from neuroinflammation, a persistent immune response inside the brain and spinal cord that contributes to neurodegenerative illnesses. Brain immunity is managed primarily by microglia, specialized immune cells residing in neural tissue that sweep up cellular debris and defend against microbes. When microglia stay overactivated for too long, they release reactive chemicals and inflammatory proteins that harm neighboring nerve cells.
Initial laboratory experiments suggested that cannabigerol could help protect brain cells from immune-related damage, with a 2018 cell-culture study indicating that pre-treating mouse motor neurons with the compound helped shield them from inflammatory proteins and cell death. Similar anti-inflammatory signs appeared in microglia themselves when a 2023 laboratory and mouse study found that modest doses of cannabigerol reduced the release of inflammatory chemicals in the same mouse microglial line used in the new study after exposure to bacterial toxins.
As consumption of cannabis-derived supplements has expanded, toxicologists have begun testing whether concentrated doses of minor cannabinoids carry hidden cellular or genetic risks. High concentrations of cannabigerol, for instance, disrupted normal cell division and produced chromosomal fragments in a 2024 toxicity study on human immune cells, although those effects occurred at levels roughly a thousand times higher than typical blood concentrations measured in human consumers.
Scientists also lacked experimental data on how cannabigerol interacts with one of the primary molecular engines of chronic brain inflammation: an intracellular multiprotein sensor complex called an inflammasome. Inside microglia, this sensor complex assembles in a two-step process when exposed to danger signals. That switches on an enzyme called Caspase-1, which releases potent inflammatory molecules and cuts a protein that punches pores in the cell membrane, killing the cell.
Led by Júlia Maiara dos Santos of the University of São Paulo in Brazil, the research team designed a dish-based study to test cannabigerol’s safety across a wide span of doses and evaluate whether non-toxic concentrations could quiet this two-step inflammasome response without harming DNA.
To evaluate basic cellular safety, the researchers cultured mouse microglial cells from an established laboratory cell line at a density of 100,000 cells per well. After overnight stabilization, the cells were exposed for 24 hours to purified cannabigerol at five concentrations (0.01, 0.1, 1, 10, and 100 micromolar, a unit measuring micromoles per liter), alongside untreated controls and a solvent control containing 0.1 percent dimethyl sulfoxide. Assays were run in triplicate, with results drawn from at least three independent experiments, and study data are available from the authors upon request.
Following the 24-hour exposure, the team measured cell survival using a dye metabolized by mitochondrial enzymes in living cells, and photographed the cells under a microscope to see whether they retracted their normal branched projections into a rounded, activated shape. They also tracked two chemical stress markers: reactive oxygen species, which are unstable oxygen-containing molecules that damage cell components when overproduced, and nitric oxide, a signaling gas that becomes inflammatory when it accumulates.
To check for genetic toxicity, the scientists paired a cell-free screening test with a whole-cell test. First, purified double-stranded DNA in a liquid solution was directly exposed to cannabigerol across the full concentration range for 30 minutes to measure the compound’s raw chemical ability to break DNA strands. Second, intact human white blood cells were treated with cannabigerol (0.01 to 10 micromolar) for 24 hours and placed on electrified gel slides in an alkaline comet assay, where broken single-stranded DNA trails behind the cell nucleus like a comet tail. Two blinded analysts scored 100 cells per sample.
Next, the authors triggered the two-step inflammasome pathway in mouse microglial cells by priming them for three hours with bacterial lipopolysaccharide (1 microgram per milliliter). They then treated the cells for two hours with cannabigerol at 0.01 to 10 micromolar and activated the complex for one hour with nigericin (10 micromolar), a bacterial antibiotic routinely used in the lab to switch the complex on. A comparison group received a selective inflammasome-blocking compound (100 nanomolar) instead of cannabigerol, after which the researchers re-evaluated cell survival, reactive oxygen species, nitric oxide, and messenger RNA levels for the Caspase-1 enzyme.
In the 24-hour safety screening, concentrations of cannabigerol up to 10 micromolar appeared well tolerated, causing no measurable cell loss. Every non-toxic dose also modestly lowered nitric oxide in unstimulated cells, to about 80 percent of untreated levels. At 100 micromolar, however, cannabigerol cut cell survival to about a fifth of untreated levels.
That highest concentration also triggered severe chemical stress, raising nitric oxide to about four times untreated levels and reactive oxygen species to roughly ten times, while microglial cells appeared to lose their branched resting structure and adopt a rounded, activated shape. Cells treated with the lower doses looked like untreated controls.
The two genetic safety tests yielded contrasting outcomes. When purified double-stranded DNA was exposed directly to cannabigerol in a cell-free solution, every concentration above 0.01 micromolar caused measurable strand breakage, with the 10- and 100-micromolar doses producing damage indices roughly two to three times the control level. Based on the combined cell-killing and DNA breakage results, the researchers excluded the 100-micromolar dose from the subsequent neuroinflammation experiments.
When intact human white blood cells were exposed to cannabigerol at concentrations up to 10 micromolar in the comet assay, however, differences in DNA damage compared to untreated cells were not statistically significant. The authors suggest this discrepancy indicates that while cannabigerol has an intrinsic chemical capacity to break bare DNA strands, living cells may shield their genetic material through built-in antioxidant defenses, metabolic breakdown, and DNA repair enzymes.
In the two-step inflammasome challenge, inducing inflammation modestly reduced microglial survival, and cannabigerol doses up to 10 micromolar helped partially restore survival to a degree matching the selective inflammasome blocker. Despite preserving cell survival, no concentration of cannabigerol attenuated the surge in reactive oxygen species triggered by the inflammatory protocol, and some doses pushed levels higher still, though these changes did not affect cell survival.
Effects on nitric oxide during the inflammatory challenge varied by dose, although the bacterial triggers alone did not produce a statistically significant rise in nitric oxide in this setup. Adding 1 micromolar of cannabigerol elevated nitric oxide production, whereas 10 micromolar lowered it compared with the inflamed group.
Meanwhile, when the team measured Caspase-1 gene expression at the 0.01-micromolar concentration (selected because it was the sole dose free of bare-DNA breakage), cannabigerol increased Caspase-1 messenger RNA to roughly 375 percent of untreated levels rather than suppressing the gene. The selective inflammasome blocker, by contrast, reduced Caspase-1 expression under the same conditions.
In the authors’ reading, these paradoxical results indicate that cannabigerol does not behave as a straightforward anti-inflammatory agent in microglia. They propose that moderate concentrations might activate protective nuclear receptors that curb nitric oxide production, whereas trace amounts might prime Caspase-1 gene transcription and very high doses may disrupt mitochondrial membranes and amplify oxidative stress.
Daniele Piomelli, a distinguished professor of anatomy and neurobiology and director of the Center for the Study of Cannabis at the University of California, Irvine, who was not involved in the research, offered a measured assessment. “This intriguing in vitro study, conducted in a single cell line, encourages us to consider cannabigerol as a potential player in the neuroinflammation space, though the modest effect sizes and narrow therapeutic window suggest that considerable work remains before any translational conclusions can be drawn,” Piomelli told PsyPost.
In pharmacology, a narrow therapeutic window means there is only a small margin between a concentration that produces beneficial effects and one that causes toxicity, making it difficult to apply dish-based results directly to human treatments. The study’s own numbers show that tight margin: 10 micromolar was the only dose that lowered nitric oxide during the inflammation challenge, and that same dose broke bare DNA in the cell-free assay.
There are a few things to keep in mind when interpreting these findings. The authors note that the immortalized mouse cell line used here differs from primary microglia taken from living tissue, and that they chose it for consistency and low cost rather than for biological fidelity. Experiments in plastic wells also cannot capture how cannabigerol behaves inside a living body, where digestive enzymes, liver metabolism, blood proteins, and the blood-brain barrier limit how much of an ingested cannabinoid ever reaches brain microglia.
Some aspects of the laboratory measurements also call for caution, as the survival assay tracks mitochondrial enzyme activity rather than directly counting dead cells. Caspase-1 was also evaluated only through messenger RNA, at a single low concentration, rather than by measuring active protein across doses. The researchers note that future work using primary brain cell cultures, three-dimensional tissue models, animal studies, and specialized mutation tests will be needed to determine whether these cellular shifts translate into real-world health risks or therapeutic benefits.
The study, “Could cannabigerol protect against neuroinflammation? Insights from an in vitro microglial study,” was authored by Júlia Maiara dos Santos, Amanda Kolinski Machado, Djenifer Leticia Ulrich Bick, Michele Rorato Sagrillo, Elaine Aparecida Del Bel, Alencar Kolinski Machado, and Antonio Cardozo dos Santos.